Insights

Strong Academic Presence Dove Medical Press specializes in open access academic publishing with a focus on science, technology, and medicine, serving a global research community. Their extensive portfolio of peer-reviewed journals, widely indexed in reputable databases like PubMed and Scopus, presents opportunities to offer complementary publishing services or targeted academic tools.

Efficient & Author-Focused With a highly satisfied author base, evidenced by high satisfaction ratings and prompt publication workflows, the company values seamless digital platforms and professional service. This opens avenues for technology providers offering innovative manuscript submission systems or author engagement platforms.

Acquisition & Growth As part of the Taylor & Francis group under Informa, Dove Medical Press benefits from backing by a major publisher, indicating growth potential in the academic publishing space. Business development opportunities exist in partnering to expand content reach, implement new digital solutions, or enhance journal marketing initiatives.

Digital & Tech Savvy The company employs advanced technologies such as PWA, HTTP/3, and cloud services, highlighting an openness to adopting innovative tech solutions. This suggests potential for collaboration on digital transformation projects, including analytics, user experience improvements, or security enhancements.

Market Opportunity Operating with revenue estimates between 1 million and 10 million dollars and a lean team, Dove Medical Press offers a strategic entry point for service providers targeting niche academic publishers. Tailored offerings in marketing, analytics, or content management could enhance their operational efficiency and global outreach.

Similar companies to Journal of Biologics, Targets & Therapy

Journal of Biologics, Targets & Therapy Tech Stack

Journal of Biologics, Targets & Therapy uses 8 technology products and services including Google Ads, Bing Ads, Cloudflare CDN, and more. Explore Journal of Biologics, Targets & Therapy's tech stack below.

  • Google Ads
    Advertising
  • Bing Ads
    Advertising Networks
  • Cloudflare CDN
    Content Delivery Network
  • RackSpace Cloud
    Data Management Platforms
  • Google Tag Manager
    Tag Management
  • YouTube
    Video Players
  • HTTP/3
    Web & Portal Technology
  • Facebook
    Widgets

Media & News

Journal of Biologics, Targets & Therapy's Email Address Formats

Journal of Biologics, Targets & Therapy uses at least 1 format(s):
Journal of Biologics, Targets & Therapy Email FormatsExamplePercentage
First@dovepress.comJohn@dovepress.com
55%
First.Last@dovepress.comJohn.Doe@dovepress.com
28%
FirstLast@dovepress.comJohnDoe@dovepress.com
14%
FirLast@dovepress.comJohDoe@dovepress.com
3%

Frequently Asked Questions

What is Journal of Biologics, Targets & Therapy's phone number?

Minus sign iconPlus sign icon
You can contact Journal of Biologics, Targets & Therapy's main corporate office by phone at . For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is Journal of Biologics, Targets & Therapy's official website and social media links?

Minus sign iconPlus sign icon
Journal of Biologics, Targets & Therapy's official website is dovepress.com and has social profiles on LinkedIn.

What is Journal of Biologics, Targets & Therapy's SIC code NAICS code?

Minus sign iconPlus sign icon
Journal of Biologics, Targets & Therapy's SIC code is 2789 - Bookbinding and Related Work NAICS code is 511 - Publishing Industries (except Internet).

How many employees does Journal of Biologics, Targets & Therapy have currently?

Minus sign iconPlus sign icon
As of January 2026, Journal of Biologics, Targets & Therapy has approximately 136 employees across 6 continents, including EuropeOceaniaAsia. Key team members include Chief Executive Officer: D. G.Head Product Manager: T. C.Editor In Chief, Nature And Science Of Sleep: A. B.. Explore Journal of Biologics, Targets & Therapy's employee directory with LeadIQ.

What industry does Journal of Biologics, Targets & Therapy belong to?

Minus sign iconPlus sign icon
Journal of Biologics, Targets & Therapy operates in the Book and Periodical Publishing industry.

What technology does Journal of Biologics, Targets & Therapy use?

Minus sign iconPlus sign icon
Journal of Biologics, Targets & Therapy's tech stack includes Google AdsBing AdsCloudflare CDNRackSpace CloudGoogle Tag ManagerYouTubeHTTP/3Facebook.

What is Journal of Biologics, Targets & Therapy's email format?

Minus sign iconPlus sign icon
Journal of Biologics, Targets & Therapy's email format typically follows the pattern of First@dovepress.com. Find more Journal of Biologics, Targets & Therapy email formats with LeadIQ.

When was Journal of Biologics, Targets & Therapy founded?

Minus sign iconPlus sign icon
Journal of Biologics, Targets & Therapy was founded in 2003.

Journal of Biologics, Targets & Therapy

Book and Periodical PublishingEngland, United Kingdom51-200 Employees

Dove Medical Press Ltd is an online open access academic publisher specialising in science, technology and especially medicine. All 70 peer-reviewed journals are free to access online, allowing authors to disseminate their research to a global audience. Most of our journals are widely indexed in databases such as PubMed, Scopus and DOAJ, and an increasing number have Impact Factors.  

We are a member of OASPA, COPE and HINARI, and are committed to publishing good scientific research and giving authors around the world the opportunity to publish and share their research findings.

We have an efficient and rigorous peer-review process. Due to this, many of our journals are able to provide authors with an initial editorial decision within four to five weeks. We aim to provide the highest possible standard of service to our authors. Recent feedback from an author survey demonstrated that:

• 100% of authors surveyed found the online manuscript system easy to use
• 100% of authors surveyed agreed that they received professional accurate service
• 97% of authors surveyed would submit a manuscript with us again 
• 96% of authors surveyed received prompt communication throughout the publishing process
• 86% of authors surveyed rated their level of satisfaction as Excellent (the other 14% rated us as good)

To view testimonials from more of our authors please visit: https://www.dovepress.com/testimonials.php

We have offices in the United Kingdom, USA and New Zealand. 
 
Dove Medical Press is part of Taylor & Francis Group, the Academic Publishing Division of Informa PLC.

Section iconCompany Overview

Phone number
SIC Code
2789 - Bookbinding and Related Work
NAICS Code
511 - Publishing Industries (except Internet)
Founded
2003
Employees
51-200

Section iconFunding & Financials

  • $1M$10M

    Journal of Biologics, Targets & Therapy's revenue is estimated to be in the range of $1M$10M

Section iconFunding & Financials

  • $1M$10M

    Journal of Biologics, Targets & Therapy's revenue is estimated to be in the range of $1M$10M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.